Answers are grounded in this paper and cite their sources.
Plexiform neurofibromas develop in 27 to 50 percent of patients with neurofibromatosis type 1.1 They cause intratumoral hemorrhages, malignant transformations, functional impairment, and disfigurement.1–3 Removal of plexiform neurofibromas can improve quality of life and prolong life.2,3 However, surgery, especially for diffuse plexiform neurofibromas, is challenging because of the risk of massive bleeding due to high vascularity and tissue fragility.1–3 Although several energy-based devices, which have been used by some surgeons for diffuse plexiform neurofibroma resection, are suggested to reduce intraoperative bleeding, few reports confirm their usefulness.2,3 In this study, we aimed to elucidate which type of energy-based device is helpful in reducing intraoperative bleeding. We reviewed the medical records of three patients with neurofibromatosis type 1 who had undergone resection of diffuse plexiform neurofibromas from January 1, 2010, to April 30, 2019, and had their tumor weights recorded. According to the energy-based devices used intraoperatively, the surgical procedures were categorized into three groups: group 1, LigaSure (Medtronic, Dublin, Ireland); group 2, Harmonic scalpel (Johnson & Johnson, New Brunswick, N.J.); and group 3, traditional electrosurgical devices. The amount of intraoperative bleeding, tumor weight, operative time, length of hospitalization, blood transfusion, and postoperative hemorrhage complications were evaluated (Table 1). This study was approved by the ethics committee at Kyoto University Graduate School and Faculty of Medicine, Kyoto, Japan (ethical approval no. R2587). The applications of LigaSure and Harmonic scalpel in diffuse plexiform neurofibroma resection are considered diversional uses. Table 1. - Summary of Backgrounds and Surgical Outcomes in the Present Study Patient Sex AAO (yr) Region EBD Intraoperative Bleeding (ml) Tumor Weight (g) Operative Time (hr:min) LOH (days) Blood Transfusion (ml) PE HC 1 F 36 Pubic region TED 150 105 2:42 65 None No None 37 Right buttock TED 1420 1438 5:36 32 None No None 37 Left buttock TED 712 615 3:05 39 None No None 38 Left thigh TED 470 385 2:50 61 None No None 38 Perineum TED 566 249 1:57 13 RCC-LR 560 No None 38 Right thigh TED 770 435 3:14 43 RCC-LR 560 No None 2 M 41 Left buttock HS 3100 1670 3:01 29 AT 1200 No None 41 Left buttock HS 800 900 6:07 27 AT 400 No None 41 Left buttock HS 4260 2250 8:59 26 AT 1200 + RCC-LR 560 + FFP 480 No None 42 Right buttock HS 390 1400 5:40 25 AT 400 No None 42 Left thigh HS 320 565 3:15 21 None No None 42 Left lower extremity HS 270 515 4:16 23 AT 400 Yes None 43 Left thigh HS 420 360 3:32 21 AT 400 Yes None 3 F 45 Back TED 880 1080 4:07 54 AT 400 No PB 53 Back LS 100 600 3:12 21 None No None 54 Left thigh LS 28 905 1:57 23 None No None AAO, age at operation; AT, autotransfusion; EBD, energy-based device; FFP, fresh frozen plasma; HC, hemorrhagic complication; HS, Harmonic scalpel; LOH, length of hospitalization; LS, LigaSure; PB, postoperative bleeding; PE, preoperative embolization; RCC-LR, red cell concentrates–leukocytes reduced; TED, traditional electrosurgical devices. Three patients underwent 16 surgical procedures in total, among which two procedures were categorized into group 1, seven into group 2, and seven into group 3. The mean intraoperative blood loss per tumor weight was 0.10 ml/g, 1.02 ± 0.65 ml/g, and 1.38 ± 0.50 ml/g in groups 1, 2, and 3, respectively (Fig. 1). The mean operative time per tumor weight was 0.22 minutes/g, 0.39 ± 0.13 minutes/g, and 0.52 ± 0.46 minutes/g in groups 1, 2, and 3, respectively. The mean length of hospitalization was 22.0 days, 24.5 ± 3.0 days, and 43.8 ± 18.0 days in groups 1, 2, and 3, respectively. There were no postoperative hematomas or other hemorrhage complications in surgeries group 1 or group 2, whereas hemorrhage complications developed in one of seven surgeries (14 percent) in group 3. No surgery required blood transfusion in group 1, wherease six of seven surgeries (86 percent) and three of seven surgeries (43 percent) required blood transfusion in groups 2 and 3, respectively.Fig. 1.: Intraoperative blood loss/tumor weight. The mean intraoperative blood loss per gram of tumor weight was 0.10 ml/g, 1.02 ± 0.65 ml/g, and 1.38 ± 0.50 ml/g in groups 1, 2, and 3, respectively. LigaSure was found to be the most effective device in reducing intraoperative blood loss in the present study.This study showed why LigaSure was the most effective device to reduce several operative risks. First, LigaSure can seal vessels up to 7 mm in diameter, and thermal spread by LigaSure is reported to be less than 2 mm.2,4,5 Second, LigaSure can measure tissue impedance automatically and fuse the vessel wall permanently based on the denatured collagen and elastin in the vessel walls.2,4,5 This automated measurement and vascular fusion may work more effectively and safely for hemostasis in diffuse plexiform neurofibromas. Since this study included only a few cases, further investigations are needed for more surgical sites at various parts of the body. In conclusion, LigaSure-assisted surgery for diffuse plexiform neurofibromas could allow for fewer hemorrhagic complications, resulting in a shorter operative time and shorter duration of hospitalization. DISCLOSURE The authors have no financial interest to declare in relation to the content of this article. No funding was received for this article.
No takes yet. Share an insight, caveat, or question.
Yoshinaga et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: